company background image
NGEN logo

NervGen Pharma TSXV:NGEN Stock Report

Last Price

CA$2.42

Market Cap

CA$169.8m

7D

-4.7%

1Y

32.2%

Updated

06 Oct, 2024

Data

Company Financials +

NGEN Stock Overview

Engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage.

NGEN fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

NervGen Pharma Corp. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NervGen Pharma
Historical stock prices
Current Share PriceCA$2.42
52 Week HighCA$3.98
52 Week LowCA$1.58
Beta1.33
11 Month Change-6.92%
3 Month Change-18.24%
1 Year Change32.24%
33 Year Change0.83%
5 Year Change86.15%
Change since IPO39.08%

Recent News & Updates

We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Jun 11
We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Recent updates

We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Jun 11
We're Interested To See How NervGen Pharma (CVE:NGEN) Uses Its Cash Hoard To Grow

Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth?

Dec 22
Is NervGen Pharma (CVE:NGEN) In A Good Position To Invest In Growth?

Here's Why We're Watching NervGen Pharma's (CVE:NGEN) Cash Burn Situation

Aug 30
Here's Why We're Watching NervGen Pharma's (CVE:NGEN) Cash Burn Situation

Will NervGen Pharma (CVE:NGEN) Spend Its Cash Wisely?

Apr 04
Will NervGen Pharma (CVE:NGEN) Spend Its Cash Wisely?

NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

Feb 02
NervGen Pharma Corp. (CVE:NGEN) Shares Could Be 31% Below Their Intrinsic Value Estimate

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Nov 23
We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

Jun 29
We Think NervGen Pharma (CVE:NGEN) Needs To Drive Business Growth Carefully

We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 16
We're Not Very Worried About NervGen Pharma's (CVE:NGEN) Cash Burn Rate

We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Mar 08
We're Keeping An Eye On NervGen Pharma's (CVE:NGEN) Cash Burn Rate

Shareholder Returns

NGENCA PharmaceuticalsCA Market
7D-4.7%0.7%0.6%
1Y32.2%-1.7%23.3%

Return vs Industry: NGEN exceeded the Canadian Pharmaceuticals industry which returned -1.7% over the past year.

Return vs Market: NGEN exceeded the Canadian Market which returned 23.3% over the past year.

Price Volatility

Is NGEN's price volatile compared to industry and market?
NGEN volatility
NGEN Average Weekly Movement7.7%
Pharmaceuticals Industry Average Movement10.2%
Market Average Movement8.2%
10% most volatile stocks in CA Market17.1%
10% least volatile stocks in CA Market3.1%

Stable Share Price: NGEN has not had significant price volatility in the past 3 months compared to the Canadian market.

Volatility Over Time: NGEN's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
2017n/aMike Kellywww.nervgen.com

NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. The company’s lead product candidate is NVG-291 that is in Phase 1b/2a clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer’s disease. It has a licensing agreement with Case Western Reserve University to research, develop, and commercialize a patented technology with therapeutic potential for spinal cord injury and other conditions associated with nerve damage.

NervGen Pharma Corp. Fundamentals Summary

How do NervGen Pharma's earnings and revenue compare to its market cap?
NGEN fundamental statistics
Market capCA$169.84m
Earnings (TTM)-CA$23.08m
Revenue (TTM)n/a

0.0x

P/S Ratio

-7.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NGEN income statement (TTM)
RevenueCA$0
Cost of RevenueCA$0
Gross ProfitCA$0
Other ExpensesCA$23.08m
Earnings-CA$23.08m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-0.33
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NGEN perform over the long term?

See historical performance and comparison